Health Information Search Results
Peer Reviewed Scientific Research Reports.
|<< Prev 20 ||Showing 1 to 10 of 10 Matches||Next 20 >>|
1. Mass screening for prostate cancer in patients with end-stage renal disease: a comparative study.
Match Strength: 8.309
OBJECTIVE: To determine the usefulness of prostate-specific antigen (PSA) screening for prostate cancer in patients with end-stage renal disease (ESRD), as although serum PSA is effective in the early detection of this cancer in the general population, there are few reports of its utility in patients with ESRD. PATIENTS AND METHODS: Blood samples were obtained for PSA screening from April 2002 to September 2003; 1250 men with ESRD aged >50 years were compared with 1007 healthy control men aged >55 years, all in Kumamoto Prefecture, Japan. All men with a serum PSA level of >4.0 ng/mL ... Read More »
» Published in BJU Int. 2006 Oct;98(4):794-7.
2. Peritoneal dialysis or hemodialysis? A dilemma for the nephrologist.
Match Strength: 6.135
Selection of the initial dialysis modality is crucial in the treatment of end-stage renal disease (ESRD) patients. Several patient- and physician-related factors play important roles in the decision between peritoneal dialysis (PD) and hemodialysis (HD). Although HD is the most common dialysis modality in the United States, in some studies PD has shown a survival advantage over HD, at least in the first 2 years of dialysis treatment, especially in non-diabetic patients and in young patients with diabetes. Other advantages accrue to early PD use in many patients. An integrated care approach ... Read More »
» Published in Adv Perit Dial. 2006;22:180-5.
3. Efficacy of the world health organization analgesic ladder to treat pain in end-stage renal disease.
Match Strength: 6.079
Pain is the one of the most common symptoms experienced by patients with ESRD; it impairs their quality of life and is undertreated. Most pain clinicians believe that the pain management approach of the World Health Organization (WHO) three-step analgesic ladder is applicable to the treatment of patients with ESRD, but this approach has not been validated for them. A cohort of 45 hemodialysis patients were assessed for type and severity of pain using the Short-Form McGill Pain Questionnaire and then treated during a 4-wk period according to the WHO analgesic ladder. Mean age was 65 +/- 12.5 yr ... Read More »
» Published in J Am Soc Nephrol. 2006 Nov;17(11):3198-203. Epub 2006 Sep 20.
4. Impact of selectin gene polymorphisms on rapid progression to end-stage renal disease in patients with IgA nephropathy.
Match Strength: 5.692
OBJECTIVE: It is evident that leukocyte infiltration plays an important role in the pathogenesis of IgA nephropathy (IgAN). Selectin is one of the key adhesion molecules involved in leukocyte infiltration. Recent studies demonstrated a significant association between the selectin gene polymorphisms and susceptibility to IgAN. However, the impact of selectin gene polymorphisms on the progression to end-stage renal disease (ESRD) has not been studied. PATIENTS AND METHODS: To evaluate the influence of the selectin gene polymorphisms on the progression of IgAN, we designed specific primers for ... Read More »
» Published in Intern Med. 2006;45(16):947-51. Epub 2006 Sep 15. Comment in: Intern Med. 2006;45(16):939-40.
5. Increasing incidence of proteinuria and declining incidence of end-stage renal disease in diabetic Pima Indians.
Match Strength: 5.420
The introduction of more efficacious treatments for diabetic kidney disease may slow its progression, but evidence for their effectiveness in populations is sparse. We examined trends in the incidence of clinical proteinuria, defined as a urinary protein-to-creatinine ratio >0.5 g/g, and diabetic end-stage renal disease (ESRD), defined as death from diabetic nephropathy or onset of dialysis, in Pima Indians with type 2 diabetes between 1967 and 2002. The study included 2189 diabetic subjects >/=25 years old. During follow-up, 366 incident cases of proteinuria occurred in the subset of ... Read More »
» Published in Kidney Int. 2006 Nov;70(10):1840-6. Epub 2006 Sep 27.
6. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
Match Strength: 5.267
OBJECTIVE: While national guidelines recommend ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy in patients with diabetes and nephropathy, guidelines concerning elderly patients with diabetes have not endorsed these drugs. We sought to assess the nephroprotective efficacy and safety of ARB therapy in elderly patients by conducting age-specific subgroup analyses using data from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study. RESEARCH DESIGN AND METHODS: We studied 1,513 patients with type 2 diabetes and nephropathy who randomly ... Read More »
» Published in Diabetes Care. 2006 Oct;29(10):2210-7.
7. Self-care management in adults undergoing hemodialysis.
Match Strength: 4.071
The research literature on self-care management for adults with end stage renal disease being treated with hemodialysis was reviewed to ascertain the current state of knowledge, identify gaps, and propose future research. Sixty-four studies were reviewed. Many studies focused on compliance and whether subjects were meeting predetermined values of outcome variables set by professionals. Self-care management of ESRD is multidimensional and warrants further research from the client professional, and health care system perspectives ... Read More »
» Published in Nephrol Nurs J. 2006 Jul-Aug;33(4):387-94; quiz 395-6.
8. Relationship between moderate to severe kidney disease and hip fracture in the United States.
Match Strength: 3.168
People with ESRD are at a high risk for hip fracture. However, the effect of moderate to severe chronic kidney disease (CKD) on hip fracture risk has not been well studied. As part of the Third National Health and Nutrition Examination Survey, information on both kidney function and history of hip fracture was obtained. This survey is a complex, multistage, probability sample of the US noninstitutionalized civilian population and was conducted between 1988 and 1994. A history of hip fracture was identified from the response to a questionnaire that was administered to all participants. There ... Read More »
» Published in J Am Soc Nephrol. 2006 Nov;17(11):3223-32. Epub 2006 Sep 27.
9. Perioperative and mid-term results of coronary bypass surgery in patients undergoing chronic dialysis.
Match Strength: 2.637
PURPOSE: The goal of this study was to evaluate perioperative and mid-term results of coronary artery bypass grafting (CABG) in patients with end-stage renal disease (ESRD). METHODS: Thirty-five consecutive dialysis patients who required CABG over a 5-year period were investigated retrospectively. RESULTS: Mean patient age was 62.5+/-11.5 years. The mean number of diseased vessels was 2.3W0.8. Off-pump CABG (OPCAB) was performed in 12 patients. The mean number of anastomoses per patient was 2.5+/-1.1. The perioperative mortality was 5.7%, and the average duration of hospitalization was 25.3+/ ... Read More »
» Published in Ann Thorac Cardiovasc Surg. 2006 Aug;12(4):257-64.
10. Risk factors for vascular complications in patients on peritoneal dialysis.
Match Strength: 2.582
The major cause of death in patients on peritoneal dialysis (PD) is vascular complications, including congestive heart failure, cerebrovascular disease, and myocardial infarction. To clarify the risk factors for vascular complications in patients on PD, we investigated the clinical course of PD in patients with and without cardiovascular and cerebrovascular complications. From among 327 end-stage renal disease (ESRD) patients initiated onto PD from April 1995 to March 2005 in the Kidney and Dialysis Center, Saitama Medical School, 8 developed de novo cardiovascular and cerebrovascular ... Read More »
» Published in Adv Perit Dial. 2006;22:192-7.
|<< Prev 20 ||Showing results 1 to 10 of 10||Next 20 >>|
* All information on Level1Diet.com is for educational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Before changing your diet, or adding supplements to your diet, or beginning an exercise program, everyone should consult a qualified and licensed health practitioner; a physician, dietician or similar professional.